In an agreement with our previous findings obtained from two commercially available melanoma cell lines, A375 and SK-MEL-28, out of four lines tested [17], we observed that patient-derived melanoma cells preconditioned with 1,25(OH)2D3 for 24 h better responded to cediranib, an oral tyrosine kinase inhibitor of VEGFR1-3, PDGFR and c-KIT [54]. The gene discussed is PDGFRB; the disease is melanoma.